ARTICLES
©2005 Nature Publishing Group doc.guandang.net
AntibodymediatedinvivodeliveryofsmallinterferingRNAsviacell-surfacereceptors
ErweiSong1,4,PengchengZhu1,4,Sang-KyungLee1,DipanjanChowdhury1,StevenKussman1,DerekMDykxhoorn1,YiFeng1,DeborahPalliser1,DavidBWeiner2,PremlataShankar1,WayneAMarasco3&JudyLieberman1
DeliveryofsmallinterferingRNAs(siRNAs)intocellsisakeyobstacletotheirtherapeuticapplication.Wedesigneda
protamine-antibodyfusionproteintodeliversiRNAtoHIV-infectedorenvelope-transfectedcells.Thefusionprotein(F105-P)wasdesignedwiththeprotaminecodingsequencelinkedtotheCterminusoftheheavychainFabfragmentofanHIV-1envelopeantibody.siRNAsboundtoF105-PinducedsilencingonlyincellsexpressingHIV-1envelope.Additionally,siRNAstargetedagainsttheHIV-1capsidgenegag,inhibitedHIVreplicationinhard-to-transfect,HIV-infectedprimaryTcells.
IntratumoralorintravenousinjectionofF105-P-complexedsiRNAsintomicetargetedHIVenvelope-expressingB16melanomacells,butnotnormaltissueorenvelope-negativeB16cells;injectionofF105-PwithsiRNAstargetingc-myc,MDM2andVEGFinhibitedenvelope-expressingsubcutaneousB16tumors.Furthermore,anErbB2single-chainantibodyfusedwithprotaminedeliveredsiRNAsspeci callyintoErbB2-expressingcancercells.Thisstudydemonstratesthepotentialforsystemic,cell-typespeci c,antibody-mediatedsiRNAdelivery.
ThereisincreasingenthusiasmfordevelopingtherapiesbasedonRNAinterference(RNAi)—post-transcriptionalgenesilencingmediatedbysmallRNAduplexesof19–23basepairs(bp).TheadvantageofRNAiliesinitshighspeci cityandpotentgenesilencing,coupledwiththefactthatitcanpotentiallytargeteverygeneandeverycellhasthenecessarymachinery(reviewedinref.1).Althoughsomequestionsremainaboutspeci cityandactivationofoff-targeteffects2–4,noneof

theseproblemshasyetbeendocumentedinvivo.Moreover,someuntowardeventscanlikelybeavoidedbyjudiciouschoiceofsequencesorchemicalmodi cationofsiRNAs.
ThemainobstacletodevelopingsiRNAasasmall-moleculedrugisdeliveringitinvivoacrossthecellmembranetothecytoplasmwhereitcanentertheRNAipathwayandguidethesequence-speci cmRNAdegradation.Intheabsenceoftransfectionreagentsorhighpressurethatmaydamagetheplasmamembrane,mostcells,includingcellsthatactivelysampletheirenvironment,suchasmacrophages,donottakeupsiRNAs.Anexceptionmaybepulmonaryepithelialcells,sinceprotectionagainstrespiratorysyncytialvirusinfectioninthelungwasachievedinonereportbynasaladministrationofsiRNAswithoutanytransfectionreagent5.EarlystudiesvalidatingthetherapeuticpotentialofsiRNAsinmiceusedhigh-pressure(so-calledhydrodynamic)intravenousinjectiontoforcesiRNAsintocells6.However,hydro-dynamicinjection,whichcausesright-sidedheartfailure,isnotpracticalforsystemichumanuse.AlthoughtransfectioncandeliversiRNAslocally,asystemicmethodtodeliversiRNAstospeci ccellsviacell-surfacereceptorswouldprovideameanstointroducesiRNAsintodesiredcellstoachievemaximaltherapeuticbene t,decreasetheamountofdrugrequiredandavoidnonspeci csilencingandtoxicityinbystandercells.
Wetookadvantageofthenucleicacid–bindingpropertiesofpro-tamine,whichnucleatesDNAinsperm,todeliversiRNAsviaananti-bodyFabfragment-protaminefusionprotein7.TheFabfragmentwasusedtoavoidpotentialsideeffectsfrominteractionsofcomplementandothermoleculeswiththeantibodyconstantregion.Asaproofofconcept,aFabantibody(F105)fragmentdirectedagainstHIV-1envelopefusedtoprotamine(F105-P)wasusedtodeliversiRNAsandsilencegeneexpressionspeci callyinHIV-infectedcellsorcellstransfectedtoexpressHIVenvelopeglycoproteingp160(HIVenv).F105-PwaspreviouslyshowntocarryplasmidDNAintoHIV-infectedcells7,8.siRNAsboundtothefusionproteinanddidnotrequirecovalentcouplingforeffectivedelivery.ThestrategywaseffectiveatdeliveringsiRNAsintoprimarycells,suchasTlymphocytes,whicharehighlyresistanttotransfection.UsingB16melanomacellstransfectedwithanexpressionvectorforHIVenv,intravenousorintratumoralinjectionofF105-P-complexedsiRNAsdeliveredsiRNAsonlyintoenv-expressing(env+)tumors,butnotintonormaltissuesorenv-negativetumors,andinhibitedtumoroutgrowthwhenthesiRNAstargetedoncogenes.Thismethodcanbegeneralizedsincewecoulduseananti-ErbB2-protaminefusionproteintodeliversiRNAsspeci callytoErbB2-expressing(ErbB2+)breastcancercells.Thisfusionprotein
InstituteforBiomedicalResearchandDepartmentofPediatrics,HarvardMedicalSchool,200LongwoodAvenue,Boston,Massachusetts02115,USA.
ofPathologyandLaboratoryMedicine,UniversityofPennsylvania,Philadelphia,Pennsylvania19104,USA.3DepartmentofCancerImmunology&AIDS,
DanaFarberCancerInstituteandDepartmentofMedicine,HarvardMedicalSchool,44BinneyStreet,Boston,Massachusetts02115,USA.4Theseauthorscontributedequallytothiswork.CorrespondenceshouldbeaddressedtoJ.L.(lieberman@cbr.med.harvard.edu).
2Department
1CBR
Publishedonline22May2005;doi:10.1038/nbt1101
NATUREBIOTECHNOLOGYVOLUME23NUMBER6JUNE2005709
Small interfering RNA-mediated down-regulation of ...antibody, as described earlier.9 Cell Growth and...In vivo imaging of siRNA delivery and silencing ...
110 Design of active small interfering RNAs Andrew S Peek & Mark A Behlke* Address Integrated DNA Technologies Inc 1710 Commercial Park Coralville IA ...
small interfering RNAs produced in bacteria Linfeng...antibody and analyzed the ability of the ...Protein mediated miRNA detection and siRNA ...
mediated by doublestranded small interfering RNA (...sequences and a suitable delivery system are ... followed by Cy3-conjugated secondary antibody (...
1人阅读 6页 2.00Selective cell death medi...
small interfering RNAs in sh embryos Surintorn ...Here we demonstrate a siRNA-mediated gene ...Western blot analysis using GFP antibody (Fig. ...
small interfering RNAs that inhibit the replication...Many primary in vivo system delivery methods (e....Lentiviral-mediated delivery of siRNAs for anti...
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors[外文期刊] 2005(06) 5.Santel A;Aleku M;Keil O;Endruschat J Esche...
small interfering RNAs (siRNAs) then guide the ...Antibody for Akt1 was purchased from Santa Cruz ...indicate that PAE mediated shAkt delivery is more...
mediated multidrug resistance via phosphorylation of ... small interfering RNA; TAMRA, 6-carboxyte...c and phospho-Ser-73-speci?c c-Jun antibody ...
热门文档